Artificial Intelligence | News | Insights | AiThority
Bitcoin
$11,772.66
+536.82
(+4.78%)
Ethereum
$405.41
+13.51
(+3.45%)
Ripple
$0.31
0
(+1.22%)
Litecoin
$59.71
+1.83
(+3.16%)
EOS
$3.08
+0.03
(+1.05%)
Cardano
$0.14
-0
(-0.69%)
Stellar
$0.11
-0
(-2.35%)
NEO
$12.90
+0.27
(+2.14%)
NEM
$0.06
-0
(-3.45%)
DigitalCash
$92.96
+5.85
(+6.72%)
Tether
$1.00
0
(+0.1%)
Binance Coin
$23.23
+0.86
(+3.84%)
QTUM
$2.78
-0.19
(-6.42%)
Verge
$0.01
-0
(-5.56%)
Ontology
$0.71
0
(+0.37%)
ZCash
$96.64
+12.02
(+14.2%)
Steem
$0.21
-0.01
(-4.22%)

Datavant Selects the Duke Clinical Research Institute as Founding Academic Partner to Accelerate Innovation in Data-Driven Clinical Research

0 1

– Datavant and the Duke Clinical Research Institute (DCRI) will work closely to engage biopharmaceutical partners and implement innovative approaches to clinical trial design and interpretation, leveraging the power of their combined datasets
– The DCRI will receive early access to Datavant’s products and data assets, and will support Datavant with its analytical and data expertise
– Initial collaboration focused on Phase 2 design in the cardiopulmonary space

Datavant, a healthcare technology company that aggregates and structures healthcare data to generate actionable insights for clinical trials, announced today that it has selected the Duke Clinical Research Institute (DCRI), the world’s largest academic clinical research organization, as an analytical partner to accelerate data-driven approaches in drug development.

As Datavant’s Founding Academic Partner, the DCRI will bring deep insights and unique perspectives on data-driven clinical research and access to clinical trial and health system data to augment Datavant’s analytical tools and data assets. The DCRI will gain early access to Datavant’s data and technology. Together, the organizations will create further opportunities to facilitate rapid scaling of best practices in clinical research to improve patient outcomes.

Michael J. Pencina
Michael J. Pencina

“New clinical insights come from matching the right question with data that can actually inform its answer,” said Michael J. Pencina, the DCRI’s Director of Biostatistics and a professor of biostatistics and bioinformatics at Duke School of Medicine. “The promise of this partnership comes from the blend of the DCRI’s analytic innovations with Datavant’s unique datasets, creating unmatched capacity for discovery.”

Travis May
Travis May

“Too many drugs fail clinical trials due to deficiencies in trial design and interpretation, depriving patients of new treatment options they desperately need. We believe that the combination of the DCRI’s analytical expertise and rich datasets combined with Datavant’s products and data hold the potential to be transformative for the industry,” said Travis May, President and Co-Founder of Datavant.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.